Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT326 + BNT327
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BNT326 + BNT327 is an investigational combination therapy being evaluated in oncology trials for advanced malignant tumors. Both agents are proprietary drug candidates developed by BioNTech. BNT326 is an antibody-drug conjugate (ADC) targeting HER3 (ERBB3), and BNT327 is a bispecific monoclonal antibody simultaneously targeting PD-L1 (programmed death-ligand 1) and VEGF-A (vascular endothelial growth factor A). The combination aims to provide synergistic anti-tumor effects by coupling direct cytotoxicity to HER3-expressing tumors (BNT326) with dual immune checkpoint inhibition and anti-angiogenic activity (BNT327). Early-phase studies are evaluating this regimen in solid tumor indications, with expansion plans announced for advanced lung and breast cancers[3][5][9].
02
Targets
VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on BNT326 + BNT327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT326 + BNT327.